Dexmedetomidine Hydrochloride (BioXcel Therapeutics)

盐酸右美托咪定 (BioXcel Therapeutics)

Report date: 2026/04/15 20:02:38

Base Information

Drug NameDexmedetomidine Hydrochloride (BioXcel Therapeutics)
Drug Alias NameSublingual film containing Igalmi (BioXcel Therapeutics)右美托咪定 (BioXcel Therapeutics)KalmPen™Sublingual film containing Dexmedetomidine (BioXcel Therapeutics)Dexmedetomidine (BioXcel Therapeutics) +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdrenergic receptors alpha-2 agonists
TargetsAdrenergic receptors alpha-2
Therapy Area/IndicationsBipolar II DisorderBipolar I DisorderAgitation +[15] 
Global Approved IndicationsAgitationSchizophreniaBipolar and Related Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/04/05
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesInveni
China Registration ClassN/A

Develop Information

Active CompaniesBioxcel Therapeutics IncNew York State Psychiatric InstituteUniversity Of North Carolina At Chapel Hill
Inactive CompaniesYale University
Active IndicationsBipolar II DisorderBipolar I DisorderAgitation +[12] 
Inactive IndicationsBipolar DisorderDeliriumAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A